ArticleAnnals of hematology2023

RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma.

Grzegorz S Nowakowski et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.